Abstract: A self-cleaning air filter assembly is provided and includes a filter housing having an upper portion and a lower portion that together define an internal volume. An air filter element is disposed in the internal volume. The upper portion of the filter housing includes a canister port adapted for fluid connection with an evaporative emissions canister. The lower portion of the filter housing includes a first port adapted for fluid connection with an atmospheric vent, and a second port adapted for fluid connection with a source of low pressure air. During a cleaning mode, air is pulled from the first port and along the filter element to the second port in order to remove particulate matter from the filter element. A vehicle evaporative emissions control system including the air filter assembly and a method of cleaning an air filter assembly are also provided.

Abstract: An evaporative emissions canister is provided. The evaporative emissions canister includes a body defining an internal volume therein for receiving one or more volumes of adsorbent. The canister body includes a port for receiving an accessory component. The port is in fluid communication with the internal volume. A sleeve seal is disposed in the port. A mounting bracket extends outwardly from the canister body. The canister body supports the accessory component, and the accessory component is secured to the canister body, thereby eliminating a hose and connector fittings between the canister body and the accessory component. A fuel system assembly including the evaporative emissions canister is also provided. A method of connecting an accessory component to an evaporative emissions canister is further provided.

Abstract: The invention relates to a new strain of Lactobacillus salivarius, products containing the new strain, the use thereof in and methods for the treatment and/or prevention of inflammation and/or infection in breast or udder tissue, particularly in a mammary gland of a human female. The inflammation and/or infection is preferably mastitis.

Abstract: The invention relates to a new strain of Lactobacillus salivarius, products containing the new strain, the use thereof in and methods for the treatment and/or prevention of inflammation and/or infection in breast or udder tissue, particularly in a mammary gland of a human female. The inflammation and/or infection is preferably mastitis.

Abstract: The present invention relates to a novel approach to prevent or treat mastitis both in humans and animals through the use of mammal milk-derived microorganisms obtained from healthy hosts of the homologous species; to those new probiotic microorganisms obtained from milk able to reduce infectious mastitis and the method of screening used for their obtaining; to the use of these probiotic bacteria for the prophylaxis or treatment against mastitis and other diseases; and finally, to compositions comprising these compounds.

Abstract: The present invention relates to a novel approach to prevent or treat mastitis both in humans and animals through the use of mammal milk-derived microorganisms obtained from healthy hosts of the homologous species; to those new probiotic microorganisms obtained from milk able to reduce infectious mastitis and the method of screening used for their obtaining; to the use of these probiotic bacteria for the prophylaxis or treatment against mastitis and other diseases; and finally, to compositions comprising these compounds.

Abstract: The present invention relates to a novel process for the selection of new probiotic strains which comprises the following steps: a) selecting for non-pathogenic strains which are capable of surviving in breast milk and/or amniotic fluid, and b) selecting for non-pathogenic strains which are able to be transferred to breast milk and/or amniotic fluid after oral intake in healthy individuals without colonizing other internal organs except mucousas. The invention also provides new Lactobacillus strains, which are: CECT5711 (Lactobacillus coryniformis), CECT5713 (Lactobacillus salivarius subsp. salivarius), CECT5714: (Lactobacillus gasseri, formerly L. acidophilus), CETC5715: (Lactobacillus gasseri), and CECT5716: (Lactobacillus fermentum); and refers to their use for the prophylaxis or treatment against digestive, infective, neuro-degenerative and immune related diseases such as allergies or inflammatory diseases.

Abstract: A semiconductor system having a pn transition and a method for manufacturing a semiconductor system are disclosed. The semiconductor system is designed in the form of a chip having an edge region, the semiconductor system includes a first layer of a first conductivity type and a second layer of a second conductivity type, which is of opposite polarity to the first conductivity type. The first layer has an edge region and a center region, the pn transition being provided between the first layer and the second layer. The second layer is more weakly doped in its edge region than in its center region, and the boundary surface of the pn transition at the edge region is non-parallel to the main chip plane.

Abstract: The present invention relates to a novel process for the selection of new probiotic strains which comprises the following steps: a) selecting for non-pathogenic strains which are capable of surviving in breast milk and/or amniotic fluid, and b) selecting for non-pathogenic strains which are able to be transferred to breast milk and/or amniotic fluid after oral intake in healthy individuals without colonizing other internal organs except mucousas. The invention also provides new Lactobacillus strains, which are: CECT5711 (Lactobacillus coryniformis), CECT5713 (Lactobacillus salivarius subsp. salivarius), CECT5714: (Lactobacillus gasseri, formerly L. acidophilus), CETC5715: (Lactobacillus gasseri), and CECT5716: (Lactobacillus fermentum); and refers to their use for the prophylaxis or treatment against digestive, infective, neuro-degenerative and immune related diseases such as allergies or inflammatory diseases.